NZ621128A - Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate - Google Patents

Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate

Info

Publication number
NZ621128A
NZ621128A NZ621128A NZ62112810A NZ621128A NZ 621128 A NZ621128 A NZ 621128A NZ 621128 A NZ621128 A NZ 621128A NZ 62112810 A NZ62112810 A NZ 62112810A NZ 621128 A NZ621128 A NZ 621128A
Authority
NZ
New Zealand
Prior art keywords
hydroxycyclopentyl
inden
ylamino
pyrrolo
pyrimidin
Prior art date
Application number
NZ621128A
Other languages
English (en)
Inventor
Reenu Chopra
Ian G Armitage
Martin Ian Cooper
Marianne Langston
Original Assignee
Millennium Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Millennium Pharm Inc filed Critical Millennium Pharm Inc
Publication of NZ621128A publication Critical patent/NZ621128A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
NZ621128A 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate NZ621128A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US21622109P 2009-05-14 2009-05-14
NZ596470A NZ596470A (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate

Publications (1)

Publication Number Publication Date
NZ621128A true NZ621128A (en) 2015-08-28

Family

ID=42396430

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ621128A NZ621128A (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
NZ596470A NZ596470A (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ596470A NZ596470A (en) 2009-05-14 2010-05-13 Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo [2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate

Country Status (18)

Country Link
US (2) US9187482B2 (enExample)
EP (2) EP3091020B1 (enExample)
JP (3) JP2012526808A (enExample)
KR (2) KR20170102381A (enExample)
CN (2) CN102421780A (enExample)
AU (1) AU2010248151B2 (enExample)
BR (1) BRPI1012142A2 (enExample)
CA (1) CA2761256C (enExample)
IL (1) IL216201A (enExample)
MX (1) MX2011012108A (enExample)
NZ (2) NZ621128A (enExample)
PE (2) PE20161222A1 (enExample)
PH (1) PH12015501925A1 (enExample)
RU (1) RU2562245C2 (enExample)
SG (2) SG10201402148SA (enExample)
UA (1) UA108986C2 (enExample)
WO (1) WO2010132110A1 (enExample)
ZA (1) ZA201108347B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008307B2 (en) 2006-08-08 2011-08-30 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of E1 activating enzymes
KR101925902B1 (ko) * 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
NZ621128A (en) 2009-05-14 2015-08-28 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
EP2635287A4 (en) * 2010-11-05 2014-06-04 Millennium Pharm Inc NEDD8 ACTIVATOR ENZYME INHIBITOR ADMINISTRATION
EA031067B1 (ru) * 2011-08-24 2018-11-30 Миллениум Фармасьютикалз, Инк. ИНГИБИТОРЫ Nedd8-АКТИВИРУЮЩЕГО ФЕРМЕНТА
AU2012321106C1 (en) 2011-11-03 2016-11-24 Takeda Pharmaceutical Company Limited Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
EP3536692B1 (en) 2012-02-17 2021-04-07 Millennium Pharmaceuticals, Inc. Pyrazolopyrimidinyl inhibitors of ubiquitin-activating enzyme
CA2880813A1 (en) 2012-08-03 2014-02-06 Millennium Pharmaceuticals, Inc. Indole-substituted pyrrolopyrimidinyl inhibitors of uba6
CN104822844B (zh) 2012-10-01 2019-05-07 米伦纽姆医药公司 预测对抑制剂的反应的生物标记物和方法以及其用途
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与
EP3016934B1 (en) 2013-07-02 2018-01-10 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
EP3517112B1 (en) 2014-07-01 2021-04-07 Millennium Pharmaceuticals, Inc. Heteroaryl compounds useful as inhibitors of sumo activating enzyme
CN106008394B (zh) * 2016-05-23 2018-12-04 中国人民解放军第二军医大学 巯基苯并噻唑酰胺类化合物及其制备与作为药物的用途
EP3684363A4 (en) * 2017-09-21 2021-05-12 Millennium Pharmaceuticals, Inc. CO-CRYSTALLINE FORMS OF ((1S, 2S, 4R) -4- {4 - [(1S) -2,3-DIHYDRO-1H-INDÉN-1-YLAMINO] -7H-PYRROLO [2,3-D] PYRIMIDIN -7-YL} -2-HYDROXYCYCLOPENTYL) METHYLSULFAMATE, THEIR FORMULATIONS AND USES
EP3930720A4 (en) * 2019-02-26 2022-12-28 Millennium Pharmaceuticals, Inc. COMPOUNDS USEFUL AS ADJUVANTS
KR20210115680A (ko) 2020-03-16 2021-09-27 서희강 연설용 프롬프터
WO2022112951A1 (en) 2020-11-25 2022-06-02 Takeda Pharmaceutical Company Limited Solid state forms of hydrochloride salt of ((1s,2s,4r)-4-{4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl)methyl sulfamate

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3622561A (en) 1969-08-18 1971-11-23 Univ Utah Nucleoside sugar esters of sulfamic acid and method for preparation of the same
US4252951A (en) * 1979-10-09 1981-02-24 Eli Lilly And Company Isolation of syn-7-(2-amino-4-thiazolyl)-(methoxyimino)acetamido-3-acetoxymethyl-3-cephem-4-carboxylic acid
JPS62108897A (ja) 1985-11-05 1987-05-20 Rikagaku Kenkyusho アスカマイシン誘導体及びその合成法並びに制癌剤
GB8813148D0 (en) 1988-06-03 1988-07-06 Glaxo Group Ltd Chemical compounds
GB8826205D0 (en) 1988-11-09 1988-12-14 Wellcome Found Heterocyclic compounds
US5726302A (en) 1989-09-15 1998-03-10 Gensia Inc. Water soluble adenosine kinase inhibitors
US5763596A (en) 1989-09-15 1998-06-09 Metabasis Therapeutics, Inc. C-4' modified adenosine kinase inhibitors
US5864033A (en) 1989-09-15 1999-01-26 Metabasis Therapeutics, Inc. Adenosine kinase inhibitors
US5674998A (en) 1989-09-15 1997-10-07 Gensia Inc. C-4' modified adenosine kinase inhibitors
US5721356A (en) 1989-09-15 1998-02-24 Gensia, Inc. Orally active adenosine kinase inhibitors
US5470898A (en) 1993-06-30 1995-11-28 Montell North America Inc. Sorbitol derivatives as nucleators and clarifiers for polyolefins, and polyolefin compositions obtained therewith
GB9325809D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
GB9325810D0 (en) 1993-12-17 1994-02-23 Zeneca Ltd Herbicidal composition
US6210917B1 (en) 1993-12-29 2001-04-03 The Regents Of The University Of California Method for suppressing multiple drug resistance in cancer cells
US5767097A (en) 1996-01-23 1998-06-16 Icn Pharmaceuticals, Inc. Specific modulation of Th1/Th2 cytokine expression by ribavirin in activated T-lymphocytes
US5973161A (en) 1996-03-18 1999-10-26 The University Of North Carolina At Chapel Hill Enantioselective synthesis of cyclopentenes
US5824657A (en) 1997-03-18 1998-10-20 Cubist Pharmaceuticals, Inc. Aminoacyl sulfamides for the treatment of hyperproliferative disorders
US6734283B1 (en) 1997-12-19 2004-05-11 Millennium Pharmaceuticals, Inc. Human proteins responsible for NEDD8 activation and conjugation
JPH11228422A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
JPH11228446A (ja) 1998-02-16 1999-08-24 Mitsubishi Chemical Corp 抗マラリア剤
KR20040028657A (ko) 2000-10-18 2004-04-03 파마셋, 리미티드 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한변형된 뉴클레오시드
AU2002364536B2 (en) 2001-12-07 2008-10-23 Vertex Pharmaceuticals, Inc. Pyrimidine-based compounds useful as GSK-3 inhibitors
WO2003106477A1 (en) 2002-06-01 2003-12-24 Isis Pharmaceuticals, Inc. Oligomeric compounds that include carbocyclic nucleosides and their use in gene modulation
EP1651595A2 (en) 2003-05-30 2006-05-03 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
US7338957B2 (en) 2003-08-28 2008-03-04 Irm Llc Compounds and compositions as protein kinase inhibitors
EP1680431A1 (en) 2003-10-17 2006-07-19 Rigel Pharmaceuticals, Inc. Benzothiazole and thiazole'5,5-b!pyridine compositions and their use as ubiquitin ligase inhibitors
EP1730122A2 (en) 2004-03-30 2006-12-13 Taisho Pharmaceutical Co., Ltd Pyrimidine derivatives and methods of treatment related to the use thereof
US20050282818A1 (en) 2004-06-22 2005-12-22 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
CA2596424C (en) 2005-02-04 2016-03-29 Millennium Pharmaceuticals, Inc. Inhibitors of e1 activating enzymes
ES2593433T3 (es) * 2006-02-02 2016-12-09 Millennium Pharmaceuticals, Inc. Inhibidores de las enzimas activadoras E1
DE602007009998D1 (de) 2006-08-08 2010-12-02 Millennium Pharm Inc Heteroarylverbindungen als hemmer der e1-aktivierenden enzyme
KR101925902B1 (ko) * 2007-08-02 2018-12-06 밀레니엄 파머슈티컬스 인코퍼레이티드 Ｅ1 활성화 효소 억제제의 합성 방법
NZ621128A (en) 2009-05-14 2015-08-28 Millennium Pharm Inc Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
AU2012321106C1 (en) 2011-11-03 2016-11-24 Takeda Pharmaceutical Company Limited Administration of NEDD8-activating enzyme inhibitor and hypomethylating agent
CN105407973A (zh) 2013-05-14 2016-03-16 米伦纽姆医药公司 Nedd8活化酶抑制剂及化学治疗剂的投与

Also Published As

Publication number Publication date
MX2011012108A (es) 2011-12-08
RU2011150826A (ru) 2013-06-20
ZA201108347B (en) 2014-05-26
EP3091020A3 (en) 2017-01-11
PE20161222A1 (es) 2016-12-01
US20160030432A1 (en) 2016-02-04
EP3091020B1 (en) 2020-12-30
US20110021544A1 (en) 2011-01-27
IL216201A0 (en) 2012-01-31
JP2017105816A (ja) 2017-06-15
IL216201A (en) 2015-11-30
KR20120024715A (ko) 2012-03-14
BRPI1012142A2 (pt) 2016-03-29
EP3091020A2 (en) 2016-11-09
CN102421780A (zh) 2012-04-18
AU2010248151B2 (en) 2016-07-14
NZ596470A (en) 2014-04-30
WO2010132110A1 (en) 2010-11-18
PH12015501925A1 (en) 2018-01-22
US9187482B2 (en) 2015-11-17
JP2012526808A (ja) 2012-11-01
SG10201402148SA (en) 2014-07-30
CN104016987A (zh) 2014-09-03
KR20170102381A (ko) 2017-09-08
US10016427B2 (en) 2018-07-10
CA2761256A1 (en) 2010-11-18
RU2562245C2 (ru) 2015-09-10
UA108986C2 (uk) 2015-07-10
EP2430026A1 (en) 2012-03-21
PE20120907A1 (es) 2012-08-18
JP2015096547A (ja) 2015-05-21
SG175929A1 (en) 2011-12-29
US20170000792A9 (en) 2017-01-05
AU2010248151A1 (en) 2011-12-01
CA2761256C (en) 2021-01-05

Similar Documents

Publication Publication Date Title
NZ621128A (en) Hydrochloride salt of ((1s,2s,4r)-4-{ 4-[(1s)-2,3-dihydro-1h-inden-1-ylamino]-7h-pyrrolo[2,3-d]pyrimidin-7-yl} -2-hydroxycyclopentyl)methyl sulfamate
IL187005A0 (en) Diacylglycerol acyltransferase inhibitors
GEP20146146B (en) Pyrrolopyrimidine compounds as inhibitors of cdk4/6
WO2009155527A3 (en) Phosphatidylinositol 3 kinase inhibitors
MX2009008540A (es) Inhibidores de virus de hepatitis c macrociclicos sustituidos con pirimidina.
MX2009012285A (es) Inhibidores de diacilglicerol aciltransferasa.
MX2009005691A (es) Inhibidores de la enzima de diacilglicerol o-acilotransferasa tipo i.
MX2012004089A (es) Inhibidores de hsp90.
EA200970500A1 (ru) СОЕДИНЕНИЯ ТЕТРАГИДРОЦИКЛОПЕНТА[b]ИНДОЛА В КАЧЕСТВЕ МОДУЛЯТОРОВ РЕЦЕПТОРА АНДРОГЕНОВ
WO2008012635A3 (en) Amine derivatives useful as anticancer agents
MY140638A (en) New heterocyclic compounds, which are active as inhibitors of beta-lactamases
TW200833663A (en) Therapeutic agents
IN2014KN02886A (enExample)
TW200833675A (en) Nicotinamide derivatives
BRPI0713555A2 (pt) ciclopenta [d] pirimidinas como inibidores de akt protéina cinase
NZ593440A (en) Aminopyrazole compounds useful for inhibiting chk1
UA94622C2 (en) Kinase innhibitor
NO20082445L (no) Neuropeptid-2 reseptor-agonister
MX2009008541A (es) Fenilcarbamatos macrociclicos que inhiben el virus de hepatitis c.
MX2009000169A (es) Derivados de purinona como agonistas de hm74a.
UA99787C2 (en) Lactams as beta secretase inhibitors
MX2009012125A (es) Compuestos terapeuticos.
TN2010000038A1 (en) Organic compounds
GEP20166481B (en) (crystalline forms of hydrochloride salt of (4a-r, 9a-s)-1-(1h-benzoimidazole-5-carbonyl)-2, 3, 4, 4a, 9, 9a-hexa- hydro-1h-indeno [2, 1-b] pyridine-6-carbonitrile and their use as hsd 1 inhibitors
IN2012DN03042A (enExample)

Legal Events

Date Code Title Description
PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 13 MAY 2017 BY HENRY HUGHES IP LIMITED

Effective date: 20160112

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 13 MAY 2018 BY COMPUTER PACKAGES INC

Effective date: 20170419

LAPS Patent lapsed